# Allogeneic Transplant in HIV Patients (BMT CTN 0903)

> **NCT01410344** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 20 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- HIV

## Interventions

- **DRUG:** Fludarabine and Busulfan
- **DRUG:** Fludarabine and Melphalan
- **DRUG:** Busulfan and Fludarabine
- **DRUG:** Cyclophosphamide and Total Body Irradiation

## Key facts

- **NCT ID:** NCT01410344
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2016-11
- **Final completion:** 2018-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-12-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01410344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01410344, "Allogeneic Transplant in HIV Patients (BMT CTN 0903)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01410344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*